{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:29:00Z","timestamp":1793302140512,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"High-level Medical Team Project in Baoan, Shenzhen","award":["202401"],"award-info":[{"award-number":["202401"]}]},{"name":"2024 High-quality Development Research Project of Shenzhen Bao'an Public Hospital","award":["BAGZL2024037"],"award-info":[{"award-number":["BAGZL2024037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04996-w","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:58:03Z","timestamp":1777028283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reshaping the therapeutic landscape of IgA nephropathy: a Bayesian network meta-analysis on the comparative efficacy and safety of immunosuppressants and targeted agents"],"prefix":"10.1186","volume":"27","author":[{"given":"Rulong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiating","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"5","key":"4996_CR1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534\u201345.","journal-title":"Kidney Int"},{"key":"4996_CR2","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","volume":"15","author":"EJ Filippone","year":"2024","unstructured":"Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol. 2024;15:1436923.","journal-title":"Front Immunol"},{"issue":"5","key":"4996_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.semnephrol.2018.05.015","volume":"38","author":"M Li","year":"2018","unstructured":"Li M, Yu XQ. Genetic Determinants of IgA Nephropathy: Eastern Perspective. Semin Nephrol. 2018;38(5):455\u201360.","journal-title":"Semin Nephrol"},{"issue":"2","key":"4996_CR4","first-page":"CD003962","volume":"2","author":"DJ Tunnicliffe","year":"2024","unstructured":"Tunnicliffe DJ, Reid S, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024;2(2):CD003962.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"4996_CR5","doi-asserted-by":"publisher","first-page":"ii40","DOI":"10.1093\/ckj\/sfad224","volume":"16","author":"F Locatelli","year":"2023","unstructured":"Locatelli F, Del Vecchio L, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii40\u20136.","journal-title":"Clin Kidney J"},{"issue":"19","key":"4996_CR6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022;327(19):1888\u201398.","journal-title":"JAMA"},{"issue":"5","key":"4996_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017;318(5):432\u201342.","journal-title":"JAMA"},{"issue":"2","key":"4996_CR8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/diagnostics13020303","volume":"13","author":"Y Du","year":"2023","unstructured":"Du Y, Cheng T, et al. IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment. Diagnostics (Basel). 2023;13(2):303.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"4996_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN, et al. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025;21(1):9\u201323.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"4996_CR10","doi-asserted-by":"publisher","first-page":"30795","DOI":"10.1038\/s41598-025-16380-z","volume":"15","author":"M Lin","year":"2025","unstructured":"Lin M, Chen S, Chen Y, et al. Exploring the molecular mechanism of budesonide enteric capsules in the treatment of IgA nephropathy based on bioinformatics. Sci Rep. 2025;15(1):30795.","journal-title":"Sci Rep"},{"issue":"Suppl 2","key":"4996_CR11","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","volume":"16","author":"SC Yeo","year":"2023","unstructured":"Yeo SC, Barratt J. The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii9\u201318.","journal-title":"Clin Kidney J"},{"issue":"2","key":"4996_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.ajkd.2017.10.004","volume":"71","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Locatelli F. Corticosteroids in IgA Nephropathy. Am J Kidney Dis. 2018;71(2):160\u20132.","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"4996_CR13","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/diagnostics15162101","volume":"15","author":"C Keskinis","year":"2025","unstructured":"Keskinis C, Pateinakis P, Stangou M. Intraglomerular Inflammation as a Guide for Mycophenolate Mofetil-Based Treatment in IgA Nephropathy. Diagnostics (Basel). 2025;15(16):2101.","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"4996_CR14","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3892\/etm.2016.3523","volume":"12","author":"QJ Wan","year":"2016","unstructured":"Wan QJ, Hu HF, He YC, et al. Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy. Exp Ther Med. 2016;12(3):1934\u20138.","journal-title":"Exp Ther Med"},{"issue":"10","key":"4996_CR15","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/joor.12540","volume":"44","author":"A De Laat","year":"2017","unstructured":"De Laat A. Network meta-analysis. J Oral Rehabil. 2017;44(10):735.","journal-title":"J Oral Rehabil"},{"issue":"7","key":"4996_CR16","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"4996_CR17","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"7414","key":"4996_CR18","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"5","key":"4996_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0272-6386(03)00194-X","volume":"41","author":"R Katafuchi","year":"2003","unstructured":"Katafuchi R, Ikeda K, Mizumasa T, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003;41(5):972\u201383.","journal-title":"Am J Kidney Dis"},{"issue":"9156","key":"4996_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353(9156):883\u20137.","journal-title":"Lancet"},{"issue":"5","key":"4996_CR21","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65(5):1842\u20139.","journal-title":"Kidney Int"},{"issue":"2","key":"4996_CR22","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","volume":"6","author":"FF Hou","year":"2023","unstructured":"Hou FF, Xie D, Wang J, et al. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(2):e2254054.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"4996_CR23","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transpl. 2005;20(10):2139\u201345.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4996_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ki.2009.499","volume":"77","author":"SC Tang","year":"2010","unstructured":"Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010;77(6):543\u20139.","journal-title":"Kidney Int"},{"issue":"5","key":"4996_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"RJ Hogg","year":"2015","unstructured":"Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis. 2015;66(5):783\u201391.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"4996_CR26","doi-asserted-by":"publisher","first-page":"452","DOI":"10.23876\/j.krcp.21.146","volume":"41","author":"SY Han","year":"2022","unstructured":"Han SY, Jung CY, Lee SH, et al. A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy. Kidney Res Clin Pract. 2022;41(4):452\u201361.","journal-title":"Kidney Res Clin Pract"},{"issue":"12","key":"4996_CR27","first-page":"796","volume":"82","author":"X Chen","year":"2002","unstructured":"Chen X, Chen P, Cai G, et al. A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy. Zhonghua Yi Xue Za Zhi. 2002;82(12):796\u2013801.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"11","key":"4996_CR28","doi-asserted-by":"publisher","first-page":"e0188375","DOI":"10.1371\/journal.pone.0188375","volume":"12","author":"MY Yu","year":"2017","unstructured":"Yu MY, Kim YC, Koo HS, et al. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study. PLoS ONE. 2017;12(11):e0188375.","journal-title":"PLoS ONE"},{"issue":"10405","key":"4996_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370.","journal-title":"Lancet"},{"issue":"10084","key":"4996_CR30","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"2","key":"4996_CR31","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.ekir.2022.01.158","volume":"7","author":"R Chaudhary","year":"2022","unstructured":"Chaudhary R, Das P, Gupta D, POS-146 AN OPEN LABEL RCT IN PROTEINURIC INDIAN IGA NEPHROPATHY PATIENTS: CAN TRF BUDESONIDE IMPROVE THE OUTCOME?. Kidney Int Rep. 2022;7(2):S63.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4996_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, et al. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2025;392(6):531\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"4996_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","volume":"105","author":"H Zhang","year":"2024","unstructured":"Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2024;105(1):189\u201399.","journal-title":"Kidney Int"},{"issue":"1","key":"4996_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2024;390(1):20\u201331.","journal-title":"N Engl J Med"},{"issue":"4S","key":"4996_CR35","first-page":"S1","volume":"100","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"11","key":"4996_CR36","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/ndt\/gfy338","volume":"34","author":"R Coppo","year":"2019","unstructured":"Coppo R. Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis. Nephrol Dial Transpl. 2019;34(11):1832\u20138.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4996_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2215\/CJN.12991117","volume":"13","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Locatelli F. Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls. Clin J Am Soc Nephrol. 2018;13(5):815\u201322.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"4996_CR38","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"10","key":"4996_CR39","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/11588390-000000000-00000","volume":"29","author":"J Menzin","year":"2011","unstructured":"Menzin J, Lines LM, Weiner DE, et al. A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy. PharmacoEconomics. 2011;29(10):839\u201361.","journal-title":"PharmacoEconomics"},{"issue":"11","key":"4996_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"issue":"7","key":"4996_CR41","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9(7):e99682.","journal-title":"PLoS ONE"},{"issue":"10","key":"4996_CR42","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8(10):e76654.","journal-title":"PLoS ONE"},{"issue":"9","key":"4996_CR43","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, et al. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. 2019;30(9):1735\u201345.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4996_CR44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker A. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4996_CR45","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.kint.2025.01.014","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Bernier-Jean A, Barratt J, et al. Treatment of patients with IgA nephropathy: a call for a new paradigm. Kidney Int. 2025;107(4):640\u201351.","journal-title":"Kidney Int"},{"issue":"12","key":"4996_CR46","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2215\/CJN.0000000839","volume":"20","author":"D Kim","year":"2025","unstructured":"Kim D, Neuen BL, Perkovic V, et al. Effects of therapies on proteinuria and eGFR in IgA nephropathy: meta-analysis of randomized trials. Clin J Am Soc Nephrol. 2025;20(12):1753\u201366.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4996_CR47","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/j.ekir.2025.03.008","volume":"10","author":"D Kim","year":"2025","unstructured":"Kim D, Neuen BL, Lv J, et al. Corticosteroid effects in IgA nephropathy by baseline proteinuria and estimated GFR. Kidney Int Rep. 2025;10(6):1886\u201395.","journal-title":"Kidney Int Rep"},{"key":"4996_CR48","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","volume":"10","author":"DV Rizk","year":"2019","unstructured":"Rizk DV, Maillard N, Julian BA, et al. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Front Immunol. 2019;10:504.","journal-title":"Front Immunol"},{"issue":"7","key":"4996_CR49","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour SJ, Coppo R, Zhang H, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019;179(7):942\u201352.","journal-title":"JAMA Intern Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04996-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04996-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04996-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:40:11Z","timestamp":1781649611000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04996-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4996"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04996-w","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study is a secondary analysis of published trial data and did not involve direct recruitment of human participants or collection of identifiable individual-level data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"359"}}